81606-47-5

Basic information

• Product Name: OTAVA-BB 1287281
• Synonyms: OTAVA-BB 1287281;Benzeneacetic acid, 3-broMo-α,α-diMethyl-
• CAS NO: 81606-47-5
• Molecular Formula: C₁₀H₁₁BrO₂
• Molecular Weight: 243.099
• Mol File: 81606-47-5.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 310.8±17.0 °C(Predicted)
• Appearance: /
• Density: 1.456±0.06 g/cm3(Predicted)
• Storage Temp.: Room temperature.
• PKA: 4.22±0.10(Predicted)
• CAS DataBase Reference: OTAVA-BB 1287281(CAS DataBase Reference)
• NIST Chemistry Reference: OTAVA-BB 1287281(81606-47-5)
• EPA Substance Registry System: OTAVA-BB 1287281(81606-47-5)

Safety Data

• Hazardous Substances Data: 81606-47-5(Hazardous Substances Data)

Usage

General Description

OTAVA-BB 1287281, also known as (E)-N-hydroxy-3-(3-piperidin-1-yl-1-phenylprop-2-en-1-ylidene)propanohydrazide, is a chemical compound with the molecular formula C18H24N4O2. OTAVA-BB 1287281 is a hydrazide derivative with potential therapeutic applications, primarily in the field of drug design and development. It has been studied for its potential bioactivity and pharmacological properties, including its ability to interact with biological targets and enzymes. Its exact mechanism of action and specific applications may vary, and further research may be needed to fully elucidate its potential uses in the pharmaceutical and medical fields.

InChI:InChI=1S/C10H11BrO2/c1-10(2,9(12)13)7-4-3-5-8(11)6-7/h3-6H,1-2H3,(H,12,13)

Upstream product

• 251458-15-8 methyl 2-(3-bromophenyl)-2-methylpropanoate 
• 81606-46-4 2-(3-bromo-phenyl)-2-methyl-propionic acid ethyl ester 
• 74-88-4 methyl iodide 
• 90433-20-8 2-(3-bromo-phenyl)-2-methyl-propionitrile 
• 53086-52-5 2-(3-bromophenyl)-propionic acid 
• 1878-67-7 3-Bromophenylacetic acid 

Downstream Products

• 885068-00-8 2-(3-boronophenyl)-2-methylpropanoic acid 
• 702639-54-1 2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-1,1'-biphenyl-3-yl}-2-methylpropanoic acid 
• 878743-65-8 2-(3-bromophenyl)-2-methylpropanoic acid chloride 
• 81606-48-6 2,2-dimethyl-2-(3-bromophenyl)ethanol 
• 90433-17-3 2-Methyl-2-(m-bromophenyl)propanal 
• 885066-67-1 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid 

Relevant articles and documents

FUSED PYRAZINE DERIVATIVES AS KINASE INHIBITORS

A series of quinoxaline derivatives, and analogues thereof, which are functionalised further by a substituted phenyl or pyridinyl moiety, being selective inhibitors of PO kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to dihydrogen phosphate salt 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid of Formula (III), a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like, by administering to said patient a pharmaceutically effective amount of the compound of Formula (III).

2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed to a compound of formula (I) wherein R1 and R2 are as defined herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutically acceptable prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the prodrug, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds of the invention in admixture with a pharmaceutically acceptable carrier, a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound of the invention.